In continuation of our efforts to further derivatize dipeptidyl peptidase IV (DPP-IV) inhibitors, a series of β-aminoacyl-containing 5-, 6-and 7-membered cyclic hydrazide derivatives was synthesized. All the compounds were evaluated for their ability to inhibit DPP-IV, and an optimum structural unit on basic skeleton is identified to show good in vitro activity.
Introduction
A non-insulin dependent diabetes mellitus (NIDDM) is characterized by chronic hyperglycemia, and belongs to a group of metabolic disorders with multiple etiologies. It is very common and may result from insulin resistance, inadequate secretion of insulin, hepatic glucose overproduction, or glucose intolerance. 
GLP-1
2 is released from L cells of the small intestine in response to digestion of food, and plays an important role in secretion of insulin. Increased activity of GLP-1 will lead to sustained insulin secretion, which normalize an elevated glucose level. It also retards gastric emptying, induction of satiety and stimulation, regeneration & differentiation of islet β-cells.
3 A dipeptidyl peptidase IV (DPP-IV), a serine protease present in many tissues, and body fluids exist either with membrane bound or soluble enzyme. It degrades amide) into inactive GLP[9-36]amide 4, 5 at N-terminus position. Inhibition of DPP-IV increases the concentration of GLP-1 as a result increases insulin secretion, 6 which can ameliorate hyperglycemia in type 2 diabetes. In recent past, several reports on use of small molecules as inhibitors of DPP-IV is available in literauture.
7
In our previous paper, 8 we have described the synthesis and biological evaluation of β-aminoacyl-containing cyclic hydrazine derivatives with only 6 examples. In continuation of our efforts, we have further derivatized the core compounds with diversified substituents, in order to find a potential candidate as DPP-IV inhibitor. We now wish to report here the detailed SAR study of β-aminoacyl-containing cyclic hydrazide derivatives as DPP-IV inhibitors.
A series of β-aminoacyl-containing cyclic hydrazine derivatives was synthesized by using the route shown in Scheme 1. The detailed synthetic explanation was described in our previous publication. 5-, 6-and 7-Membered cyclic hydrazide derivatives with β-aminoacyl group were evaluated in vitro for their inhibitions against DPP-IV. MK-0431 was used as a reference compound. Compounds which showed more than 50% inhibition of DPP-IV at 100 nM, were considered as promising and the IC 50 values of the compounds were determined. The data are compared with ring size and also various functionalities such as acyl, benzoyl, urea, sulfonyl, carbamate, and alkyl groups. Basic compounds (R = H, 5-1, 6-1 and 7-1) couldn't reach 50% inhibition at 100 nM, however benzoyl substituents promoted activity. More particularly 6-and 7-membered benzoyl hydrazides (6-2 and 7-2) showed good in vitro inhibitory activities with IC 50 values Figure 1 . β-aminoacyl-containing cyclic hydrazide derivatives. of 74.40 nM and 85.72 nM respectively. In case of urea, 7-membered hydrazide displayed a good activity with 95.07 nM. All other substituents such as sulfonyl, carbamate and aralkyl groups showed weak activities.
The benzoyl derivatives (6-2 and 7-2) being demonstrated good activity further derivatized with various substituted benzoyl derivatives and evaluated. Some compounds (7-11, 7-13, 7-14, 7-15, 7-17, 7-18 and 7-22) showed good activities and compound (7-18) is found to be most active with an IC 50 value 32.80 nM. The details are tabulated in Table 2 .
Urea based substituent also being active, it is further derivatized with various substituents and evaluated. Compound 7-39 showed better activity than other urea based derivatives, and the details of activity data is tabulated in Table 3 .
From the SAR data, we have chosen compound 7-18 to evaluate in vivo for their ability to reduce DPP-IV activity in normal C57BL/6J mice. Oral administration of compounds 7-18, at 10 mg/kg dose, resulted in ca 70% inhibition of plasma DPP-IV activity after 2 h.
Conclusion
Diverse β-aminoacyl-containing 5-, 6-and 7-membered cyclic hydrazide derivatives were synthesized and evaluated for their ability to inhibit dipeptidyl peptidase IV (DPP-IV). Among them, 7-18 emerged as the most active compound with an IC 50 value of 32.8 nM, and evaluated for its in vivo DPP-IV inhibitory activity.
Experimental
General. All reported yields are isolated yields after column chromatography or crystallization.
1
H-NMR spectra were obtained on FT-NMR Varian GEMINI-200FT or Bruker AVANCE-300 with TMS as internal reference. MS spectra were obtained on a Shimadzu QP5050 spectrograph.
Synthetic Procedure for Representative Compound 7-18: A mixture of (R)-tert-butyl 4-(1,2-diazepan-1-yl)-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-ylcarbamate (30 mg, 0.072 mmol), Benzo [1, 3] dioxole-5-carbonyl chloride (20 mg, 0.108 mmol), and triethylamine (20 μL, 0.144 mmol) in CH 2 Cl 2 (2 mL) was stirred for 1 h at room temperature. The reaction mixture was diluted with brine and CH 2 Cl 2 . The organic layer was separated, dried and evaporated. The residue was purified by silica gel column chromatography to give (R)-tert-butyl 4-(2-(benzo[d] [1, 3] dioxole-5-carbonyl)-1,2-diazepan-1-yl)-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-ylcarbamate (36 mg, 89%) as an oil. 47 (m, 6H) .
Determination of Inhibitory Activity against DPP-IV. 10 μL of Caco-2 cell lysate was suspended in Tris-HCl (pH 7.5), and then 40 μM Ala-Pro-AFC (ICN Biomedicals, Inc) was added. After treatment of compounds, the mixture was incubated for 60 min at 24 o C. AFC as a indicator of DPP-IV activity was detected at 405/510 nm (Ex/Em) by Fluorometer, Synergy HT (Biotek). IC 50 was calculated by Prism 4.0 software (GarphPad Software, Inc).
